Email Updates

You are here


To save lives, HIV treatment alone isn’t enough. Suppressing HIV is what matters.

In 2011, a landmark clinical trial showed that early initiation of anti-retroviral therapy (ART) for people who are HIV-infected cuts the risk of HIV transmission by a stunning 96 percent. The trial provided powerful new momentum to global efforts to expand treatment access — both for the health of individuals living with HIV and for the potential to prevent millions of new infections.

Getting people onto treatment, though, is only half the story. To save lives and slow the HIV epidemic, treatment needs to achieve long-term virologic suppression — meaning the level of HIV in a person’s body is essentially undetectable. In most countries, only a minority of people with HIV have their virus in check. To make viral suppression the norm, better adherence programs, viral load monitoring and other steps are urgently needed.

What We're Reading

Long-acting formulations are being developed to overcome barriers—primarily, adherence—presented by daily oral therapy. Encouraging results regarding adherence comes from the phase IIb LATTE-2 study (NCT02120352) evaluating long-acting cabotegravir-rilpivirine for HIV treatment where 99 percent of participants preferred to continue with injectable therapy compared with 78 percent on oral treatment. The purpose of this article is to provide an overview of the various ART therapies being studied and are available for prevention and treatment of HIV.

June 24, 2021
Contagion Live

In a major milestone that will curb pill fatigue and reduce default cases, Zimbabwe will among other countries introduce a new HIV preventive drug that will be taken only once a month.

June 20, 2021
Bulawayo 24 News
Subscribe to RSS - Treatment